| |

Understanding Malignant Pleural Mesothelioma: What You Need to Know

Understanding Malignant Pleural Mesothelioma: What You Need to Know

Malignant pleural mesothelioma is a rare cancer caused by asbestos. It starts in the lining of the lungs and can cause symptoms similar to tuberculosis. A new article published in Respiratory Medicine provides a modern, comprehensive clinical overview of malignant pleural mesothelioma. The article provides an in-depth summary of everything you need to know.

Navigating Malignant Pleural Mesothelioma

Malignant pleural mesothelioma is not very common. In fact, only around 30,000 new cases were reported worldwide in 2020. This kind of cancer tends to affect older patients more, especially those over 40, and is more common in men. Malignant pleural mesothelioma is caused by exposure to asbestos, a material used in old buildings.

The way malignant pleural mesothelioma grows in the body can look different depending on the type. Doctors often split it into three categories based on the cells’ appearance under a microscope. Each type might need different kinds of treatment.

But how do you know if someone has malignant pleural mesothelioma? Well, it can be tricky because the symptoms, like trouble breathing or chest pain, can seem like other problems. Doctors might use different tests like imaging or biopsies to figure it out. Some specific tests, like staining cells in a lab, help doctors confirm if it’s malignant pleural mesothelioma or something else.

Decoding Mesothelioma Treatment

Treating mesothelioma is tough, and there’s no one-size-fits-all solution. Different treatments, like chemotherapy or radiation, can be used alone or together. Surgery might also be an option for some patients, especially in the early stages of the disease.

But getting the proper treatment can be really complicated. Sometimes, by the time someone is diagnosed, the cancer has already spread a lot, making it harder to treat. And since mesothelioma is rare, not all doctors might know the best ways to manage it.

That’s why different doctors must work together. A group of experts from different fields can discuss each patient’s case and determine the best plan. This kind of team, a multidisciplinary tumor board, can make a big difference in how well someone is treated.

In the end, malignant pleural mesothelioma is a tough cancer. There’s ongoing research to find better ways to diagnose and treat it. By raising awareness and supporting more studies, we can hope for better outcomes for those affected by this rare disease.

Source:

Khan, Agha Muhammad Hammad, Shaikh Hasan Anwer, Samad Sayed, Muhammad Atif Mansha, Yazdan Bin Kamran, Afrah Khursheed, Fahd Haroon, Niaz Hussain Soomro, Romana Idrees, and Ahmed Nadeem Abbasi. “Comprehensive Clinical Overview of Malignant Pleural Mesothelioma.” Respiratory Medicine, December 30, 2023, 107511. https://doi.org/10.1016/j.rmed.2023.107511.

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Mesothelioma Blood Test May Be Possible

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…